Apremilast in Refractory Alopecia Areata.

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Alopecia areata is a common autoimmune condition causing nonscarring hair loss.
• Current treatments for extensive alopecia areata are often unsatisfactory, with systemic immunosuppressants carrying significant side effects.
• Apremilast, a phosphodiesterase 4 inhibitor, is approved for psoriasis and psoriatic arthritis but has shown variable efficacy in alopecia areata.

Observation:

• This report presents four cases of extensive alopecia areata.
• All patients received treatment with apremilast.

Findings:

• All four patients with extensive alopecia areata experienced significant hair regrowth.
• These findings suggest apremilast may be an effective treatment option for severe AA.

Implications:

• Apremilast offers a potential therapeutic avenue for patients with extensive alopecia areata.
• Further clinical trials are warranted to confirm the efficacy and safety of apremilast in AA treatment.
• This study contributes to the understanding of targeted therapies for autoimmune-induced hair loss.